HMI-102 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 240 | Phenylketonuria | 1 |
240. Phenylketonuria
Clinical trials : 143 / Drugs : 90 - (DrugBank : 10) / Drug target gene : 1 - Drug target pathways : 5
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03952156 (ClinicalTrials.gov) | June 10, 2019 | 9/5/2019 | Gene Therapy Clinical Study in Adult PKU | A Phase 1/2 Open-Label, Randomized, Concurrently-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of HMI-102 in Adult PKU Subjects With PAH Deficiency | Phenylketonurias;PAH Deficiency | Genetic: HMI-102 | Homology Medicines, Inc | NULL | Active, not recruiting | 18 Years | 55 Years | All | 28 | Phase 1/Phase 2 | United States |